Boston Scientific has surged 40.5% in the past year, outpacing both its industry and the S&P 500. The WATCHMAN FLX and ...

The emergence of generative artificial intelligence (AI) indicates a paradigm shift in military research and application, ...

Boston Scientific reached an all-time high of $107.2 per share, buoyed by a 40.16% annual gain and stellar financials.

Thermo Fisher Scientific’s Accelerator™ Drug Development solutions, which integrate services for contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) ...

For the full year, Boston Scientific sees adjusted EPS of $2.87 to $2.94 and sales up 15% to 17%, above Visible Alpha projections.

Boston Scientific had increased its debt leverage to acquire new products in 2015-16 and reduced debt through 2017-18, only to increase it again in late 2018 to accommodate the acquisition of BTG ...

Jerusalem Post / Business & Innovation Boston Scientific acquires Israeli medtech firm SoniVie for up to $540M SoniVie’s ultrasound innovation leads to $540M Boston Scientific buyout.

Boston Scientific expects organic revenue growth of 14% to 16% in the first quarter and 10% to 12% for full-year 2025, driven ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Boston Scientific Corp (NYSE:BSX) stands against the ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant strides in recent years, positioning itself as a frontrunner in the ...

Boston Scientific Corporation today announced it has entered into a definitive agreement to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based ...

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative treatments. Click for more on AXNX stock.